Core Viewpoint - Ascentage Pharma-B (06855) shares rose nearly 4%, currently up 3.69% at HKD 53.4, with a trading volume of HKD 61.64 million [1] Group 1: Company Developments - On January 7, Ascentage Pharma announced via its official WeChat account that its novel BTK-targeted protein degrader APG-3288 has received IND approval from the US FDA, allowing the company to initiate clinical research for treating relapsed/refractory B-cell malignancies [1] - This marks a significant advancement in the company's research and development efforts in the field of targeted protein degradation, officially entering the clinical stage [1] - The study will be a global, multicenter, open-label Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies [1]
港股异动 | 亚盛医药-B(06855)涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可